ClinicalTrials.gg
TerminatedNCT02047500Updated May 11, 2025Results posted

Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer

A Phase 1 interventional study of TH-302 and Nab-paclitaxel in Pancreatic Cancer, sponsored by ImmunoGenesis. Terminated at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-11.

Sponsored by ImmunoGenesis · Phase 1, Interventional, and Treatment

Why this study was terminated
The trial has been terminated earlier following the company decision to discontinue the clinical development of Evofosfamide

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
19
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,851 studies in Pancreatic Neoplasms with a site in United States — 300 open to participants now, 474 under way, 25 of them phase 3. Pancreatic Neoplasms · United States.

Enrollment
1,120th of 1,574
19 · median 37
Started
2014
with 63 others
Phase 1
556 of 1,851
76 open now
Registered
788th of 1,851
by date

Among the 1,851 studies in Pancreatic Neoplasms with a site in United States, this one is the 1,120th largest by enrollment of the 1,574 interventional ones that give a count, is one of 64 that started in 2014, is one of 556 in phase 1, and was the 788th registered.

Pancreatic Neoplasms

3,897 studies on the registry are indexed under Pancreatic Neoplasms; 1,003 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

300 of the 1,851 studies in Pancreatic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

295 more — sign in →

All 300 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 743 Pancreatic Neoplasms studies recruiting now, 477 (64%) set no upper age limit and 151 (20%) stop at 75 or younger; 40 take children under 18; 59 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,851 studies in Pancreatic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This is a multicenter, open-label, Phase 1, dose escalation trial to evaluate the safety, tolerability, and recommended Phase 2 dose (RP2D) of TH-302 in combination with gemcitabine and nab-paclitaxel in previously untreated subjects with locally advanced unresectable or metastatic pancreatic adenocarcinoma.

03

Conditions studied

  • Pancreatic Cancer

Keywords

  • TH-302
  • Nab-paclitaxel
  • Gemcitabine
  • Evofosfamide
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects greater than or equal to (>=) 18 years of age with locally advanced unresectable or pancreatic adenocarcinoma proven by histology or cytology and previously untreated with chemotherapy or systemic therapy other than:

    • Radiosensitizing doses of 5-fluorouracil;
    • Radiosensitizing doses of gemcitabine if relapse occurred at least 6 months after completion of gemcitabine;
    • chemotherapy if relapse occurred at least 6 months after surgical resection;
    • Adjuvant chemotherapy if relapse occurred at least 6 months after completion of adjuvant chemotherapy
  • Subjects may have measurable or non- according to 1.1.
  • (ECOG) performance status of 0 or 1
  • Acceptable hematological status, liver and renal function as defined in the protocol
  • Other protocol defined inclusion criteria could apply

Exclusion criteria

Exclusion Criteria:

  • Significant cardiac or peripheral vascular arterial disease
  • Known brain, or epidural (unless treated and well controlled for at least 3 months)
  • Severe chronic obstructive or other pulmonary disease with hypoxemia
  • Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy
  • Subjects receiving concomitant treatment with radiotherapy or other drugs
  • Other protocol defined exclusion criteria could apply
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    TH-302 plus Nab-paclitaxel plus Gemcitabine

    Drug: TH-302 · Drug: Nab-paclitaxel · Drug: Gemcitabine

Interventions

  • DrugTH-302

    TH-302 will be administered at a dose ranging from 170-340 milligram per square meter (mg/m\^2) as intravenous infusion over 30 minutes on Days 1, 8 and 15 of every 28-day cycle until evidence of progressive disease, intolerable toxicity or subject withdrawal.

  • Nab-paclitaxel will be administered at a dose ranging from 100-125 mg/m\^2 as intravenous infusion over 30 minutes on Days 1, 8 and 15 of every 28-day cycle until evidence of progressive disease, intolerable toxicity or subject withdrawal.

  • Gemcitabine will be administered at a dose ranging from 800-1000 mg/m\^2 as intravenous infusion over 30 minutes on Days 1, 8 and 15 of every 28-day cycle until evidence of progressive disease, intolerable toxicity or subject withdrawal.

06

What researchers measure

Primary outcomes

  1. Number of Subjects Experiencing Dose Limiting Toxicity (DLT)

    Time frame: Up to Day 28 of Cycle 1

Secondary outcomes

  1. Progression Free Survival (PFS) Time

    Time frame: Time from enrollment to progressive disease (PD) or occurrence of death due to any cause within 120 days of either first administration of study drug or the last tumor assessment

  2. Percentage of Subjects With Objective Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v 1.1) Criteria

    Time frame: Every 8 weeks from Day 1 of Cycle 1 until disease progression or within 1 week after discontinuation of study treatment

  3. Duration of Overall Response According to RECIST Version 1.1 Criteria

    Time frame: Every 8 weeks from Day 1 of Cycle 1 until disease progression or within 1 week after discontinuation of study treatment

  4. Percentage of Subjects With Disease Control According to RECIST Version 1.1 Criteria

    Time frame: Every 8 weeks from Day 1 of Cycle 1 until disease progression or within 1 week after discontinuation of study treatment

  5. Tumor Metabolic Response Assessed by Positron Emission Tomography (PET) Scans According to European Organization for Research and Treatment of Cancer (EORTC) Criteria

    Time frame: Baseline and 8 weeks after Day 1 of Cycle 1

  6. Number of Subjects With Treatment-emergent Adverse Events (TEAEs)

    Time frame: Baseline up to Day 30 after the last dose of study treatment

07

Results

Posted Dec 15, 2017

Participant flow

Participant flow — Overall Study
MilestoneTH-302 Plus Nab-paclitaxel Plus Gemcitabine
Started19
Completed0
Not completed19

Outcome measures

PrimaryNumber of Subjects Experiencing Dose Limiting Toxicity (DLT)
Time frame:
Up to Day 28 of Cycle 1
Reported as:
Count of participants · Participants
Number of Subjects Experiencing Dose Limiting Toxicity (DLT)
ParticipantsTH-302 Plus Nab-paclitaxel Plus Gemcitabine
Number of Subjects Experiencing Dose Limiting Toxicity (DLT)1
SecondaryProgression Free Survival (PFS) Time
Time frame:
Time from enrollment to progressive disease (PD) or occurrence of death due to any cause within 120 days of either first administration of study drug or the last tumor assessment

Results for this outcome have not been posted.

SecondaryPercentage of Subjects With Objective Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v 1.1) Criteria
Time frame:
Every 8 weeks from Day 1 of Cycle 1 until disease progression or within 1 week after discontinuation of study treatment

Results for this outcome have not been posted.

SecondaryDuration of Overall Response According to RECIST Version 1.1 Criteria
Time frame:
Every 8 weeks from Day 1 of Cycle 1 until disease progression or within 1 week after discontinuation of study treatment

Results for this outcome have not been posted.

SecondaryPercentage of Subjects With Disease Control According to RECIST Version 1.1 Criteria
Time frame:
Every 8 weeks from Day 1 of Cycle 1 until disease progression or within 1 week after discontinuation of study treatment

Results for this outcome have not been posted.

SecondaryTumor Metabolic Response Assessed by Positron Emission Tomography (PET) Scans According to European Organization for Research and Treatment of Cancer (EORTC) Criteria
Time frame:
Baseline and 8 weeks after Day 1 of Cycle 1

Results for this outcome have not been posted.

SecondaryNumber of Subjects With Treatment-emergent Adverse Events (TEAEs)
Time frame:
Baseline up to Day 30 after the last dose of study treatment

Results for this outcome have not been posted.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TH-302 Plus Nab-paclitaxel Plus Gemcitabine—19/19 (100%)19/19 (100%)
Most frequent serious events
Showing 10 of 22
Most frequent serious events
EventTH-302 Plus Nab-paclitaxel Plus Gemcitabine
SepsisInfections and infestations3/19
PneumoniaInfections and infestations2/19
PancytopeniaBlood and lymphatic system disorders2/19
Cellulitis of male external genital organInfections and infestations1/19
Urinary tract infectionInfections and infestations1/19
Febrile neutropeniaBlood and lymphatic system disorders1/19
HypokalaemiaMetabolism and nutrition disorders1/19
PresyncopeNervous system disorders1/19
SyncopeNervous system disorders1/19
Cardiac failure congestiveCardiac disorders1/19
Most frequent other events
Showing 10 of 62
Most frequent other events
EventTH-302 Plus Nab-paclitaxel Plus Gemcitabine
ThrombocytopeniaBlood and lymphatic system disorders15/19
NeutropeniaBlood and lymphatic system disorders14/19
FatigueGeneral disorders14/19
AnaemiaBlood and lymphatic system disorders13/19
NauseaGastrointestinal disorders13/19
AlopeciaSkin and subcutaneous tissue disorders12/19
RashSkin and subcutaneous tissue disorders10/19
Decreased appetiteMetabolism and nutrition disorders9/19
Peripheral sensory neuropathyNervous system disorders9/19
DiarrhoeaGastrointestinal disorders9/19

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)TH-302 Plus Nab-paclitaxel Plus Gemcitabine
<=18 years0
Between 18 and 65 years11
>=65 years8
Sex: Female, Male
Sex: Female, Male(Participants)TH-302 Plus Nab-paclitaxel Plus Gemcitabine
Female10
Male9
Region of Enrollment
Region of Enrollment(participants)TH-302 Plus Nab-paclitaxel Plus Gemcitabine
United States19
08

Study locations

5 sites
  • Mayo Clinic
    Scottsdale, Arizona 85259, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Washington University
    Saint Louis, Missouri 63110, United States
  • Fox Chase Cancer Center
    Philadelphia, Pennsylvania 19111, United States
09

References and documents

Publications

  • Sun JD, Liu Q, Ahluwalia D, Li W, Meng F, Wang Y, Bhupathi D, Ruprell AS, Hart CP. Efficacy and safety of the hypoxia-activated prodrug TH-302 in combination with gemcitabine and nab-paclitaxel in human tumor xenograft models of pancreatic cancer. Cancer Biol Ther. 2015;16(3):438-49. doi: 10.1080/15384047.2014.1003005. PubMed 25679067 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2014, a primary completion of Sep 2015 and a completion of May 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2017, 2 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 24, 2014
First posted
Jan 28, 2014
Start
Jan 2014
Primary completionActual
Sep 2015
CompletionActual
May 2016
Results first posted
Dec 15, 2017
Last update
May 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02047500
Lead sponsor
ImmunoGenesis
Collaborators
Threshold Pharmaceuticals
Responsible party
Sponsor
First posted
Jan 28, 2014
Start date
Jan 2014
Primary completion
Sep 2015
Completion
May 2016
Results posted
Dec 15, 2017
Last update
May 11, 2025

Study contacts

Medical Responsible
study director · EMD Serono Inc., a business of Merck KGaA, Darmstadt, Germany
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TH 302

Start the discussion